DISCOVER: A single-site double-blind placebo-controlled randomized mechanistic crossover trial to assess the influence of boDy weIght on aSpirin-triggered speCialized prO-resolVing mEdiatoRs

Brief description of study

Aspirin is commonly used to prevent heart attacks and strokes in clinical care. Commonly a “baby” aspirin (81mg) is prescribed for this purpose. However, higher doses may work better in individuals who weigh more. This study will investigate how body weight influences aspirin’s ability to reduce inflammation. Aspirin is Food and Drug Administration (FDA) approved for the temporary relief of minor aches and pains, to temporarily reduce fever, and to reduce the chances of a heart attack, stroke and death in people with severe atherosclerosis. In this research study, the use of aspirin is considered ‘off-label’ and therefore investigational. To participate in the study, you must take the study medication (aspirin or placebo) daily over the course of 12 weeks and attend 5 study visits.

Clinical Study Identifier: s20-01884 Identifier: NCT04697719
Principal Investigator: Sean P. Heffron.

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.